PFBT
CRSP icon

Parkside Financial Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.57K Hold
75
– – ﹤0.01% 1925
2025
Q4 		$3.93K Buy
75
+25
+50% +$1.5K ﹤0.01% 1884
2025
Q3 		$3.24K Buy
+50
New +$2.87K ﹤0.01% 1862

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkside Financial Bank & Trust's CRSP Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 75 shares worth $3.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1925.

Parkside Financial Bank & Trust first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.93K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Parkside Financial Bank & Trust held 75 shares of CRISPR Therapeutics worth $3.57K as of Q1 2026.
  • Parkside Financial Bank & Trust left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #1925 holding.
  • Parkside Financial Bank & Trust first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Parkside Financial Bank & Trust's CRISPR Therapeutics position peaked at $3.93K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.